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Introduction
Diabetic retinopathy (DR) is one of the most frequent complications of diabetes. Approximately 75% of patients living with diabetes for 20 years show clinical signs of retinopathy and over 10% of them are affected by a vision loss (Frank, 2004; Hernandez et al., 2017) . Vision loss is the result of slow and gradual alterations in the microvasculature of the retina due to hyperglycaemia and an inflammatory response, which lead to the overexpression of VEGF, breakdown of the bloodretinal barrier, pathological proliferation of blood vessels and the formation of fibrous tissue in the vitreous cavity leading to retinal detachment (Wilkinson-Berka, 2006) . In addition to changes in the vascular bed, pathological mechanisms in DR are associated with activation of glial cells and dysfunction of neurons. Principally, reactive microglia, astrocytes and Müller glial cells in the retina produce VEGF (Wang et al., 2010; 2015) and inflammatory mediators that amplify the inflammatory response (Chang et al., 2007; Sorrentino et al., 2016) and could play an important role in the breakdown of the haematoretinal barrier (Antonetti et al., 1998; Wang et al., 2010) . Recent findings suggest a role for the kallikrein-kinin system in the development of inflammation in DR (Wilkinson-Berka and Fletcher, 2004; Phipps and Feener, 2008; Feener, 2010; Bhat et al., 2014) . All the components of the kallikrein-kinin system are present in the retina and several studies suggest that metabolic changes associated with diabetes can cause the production of kinins in the retina (Ma et al., 1996; Takeda et al., 1999; Phipps et al., 2009) . Although retinal vascular permeability was decreased following systemic and intravitreal injection of a selective plasma kallikrein inhibitor in diabetic rats (Clermont et al., 2011) , the relative contribution of tissue kallikrein in DR remains elusive.
Kinins are vasoactive autacoid peptides involved in a variety of biological effects including vasodilatation, inflammation and pain. Kinins are among the first mediators to be released into the injured tissue (Couture et al., 2001) . Kinins undergo rapid metabolic degradation by amino-, endo-and carboxypeptidases found in blood, tissues and biological fluids. The aminopeptidases, carboxypeptidases, neutral endopeptidase and angiotensin converting enzyme (also known as kininase II) are the main enzymes responsible for the metabolism of bradykinin (BK) and kallidin (Lys-BK) into active and inactive peptide fragments. These enzymes ensure that the half-life of kinins is only a few seconds (Décarie et al., 1996; Gabra et al., 2003) . Kinins exert their biological effects by activating two GPCRs: the bradykinin B 1 receptor and B 2 receptor (Regoli et al., 2001; Leeb-Lundberg et al., 2005) . The constitutive B 2 receptor mediates most of the effects of BK and kallidin while the B 1 receptor is activated by the C-terminal metabolites des-Arg 9 -BK and Lys-desArg 9 -BK generated by kininase I (carboxypeptidase M/N).
The B 1 receptor is weakly expressed under physiological conditions, yet it is strongly induced and up-regulated during tissue injury or after exposure to oxidative stress, bacterial endotoxins, growth factors and pro-inflammatory cytokines such as TNF-α and IL-1β (Zhou et al., 1998; Couture et al., 2014) . The induction of B 1 receptors by cytokines is regulated by MAPK and the nuclear transcription factor NF-kB (Larrivee et al., 1998; Campos et al., 1999) . The B 1 receptor is overexpressed in the retina of type 1 and type 2 diabetic patients (Bhat et al., 2014) . In the retina of streptozotocin (STZ)-diabetic rats, the B 1 receptor is readily up-regulated by a mechanism involving oxidative stress, and contributes to the vasodilatation of microvessels and increased vascular permeability (Abdouh et al., 2003; Abdouh et al., 2008) . The nonpeptide B 1 receptor antagonist LF22-0542 reverses numerous of the pathological processes, occurring after two weeks in retina from STZ-diabetic rats, such as vascular hyperpermeability, leukocyte infiltration and the upregulation of inflammatory mediators notably VEGF (Pouliot et al., 2012) . To better define the physiopathological role of the B 1 receptor in DR, we investigated its cellular distribution and its expression during the course of diabetes. For this study, we focused on the nonproliferative stage of DR, and selected 2 weeks of diabetes in most experiments to enable comparison with our previous studies using LF22-0542 (Pouliot et al., 2012 
Methods

Animal model and procedures
All experimental methods and animal care procedures were approved by the animal care committee of the Université de Montréal (Protocol 15-063) in accordance with the Canadian Council on Animal Care. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Male Wistar rats (200-250 g, 6-8 weeks old) were purchased from Charles River Laboratories (St-Constant, QC, Canada) and housed two per cage using heated wood chip litter as bedding material in a pathogen-free environment and under standard conditions of temperature (22°C) and humidity (43%) on a 12 h light/dark cycle and allowed free access to normal chow diet and tap water. The rats were made diabetic by a single i.p. injection of STZ (Zanosar 65 mg·kg À1 ; Sigma-Aldrich, Oakville, ON, Canada). The concentration of glucose was measured in blood samples from the tail vein with a glucometer (Accusoft; Roche Diagnostics, Laval, QC, Canada). Only STZ-treated rats with glycaemia above 20 mmol·L À1 were considered diabetic and included in the study. Blood glucose and body weight were recorded three times per week and on the day of the experiment. STZ-diabetic rats were humanely killed with isoflurane when they reached the following ethical endpoints: glycaemia ≥30 mmol·L À1 , loss of body weight ≥20%, severe diarrhoea, loss of locomotor activity and rearing. STZdiabetic rats were randomly divided for each pharmacological treatment, and the experimenter was blinded to assess immunohistological parameters (B 1 receptor distribution, microgliosis and leukostasis) and to perform data analysis. One rat was killed in the STZ treated group with R-838 because the glycaemia was higher than the endpoint.
Pharmacological treatments
The highly selective and metabolically protected peptide B 1 receptor agonist R-838 (Audet et al., 1997) synthesized at the Research Institute of Biotechnology, National Research Council of Canada (Montréal, QC, Canada) was injected intravitreally (100 ng·5 μL À1 ) twice, to rats anaesthetized with 3% isoflurane, the second injection being given 48 h prior to the experiments. The vehicle (sterile saline solution, 0.9%) was administered to the contralateral eye. Rats with any kind of postoperative complication (cataract or infection) were excluded from analysis. A selective and metabolically protected peptide B 1 receptor antagonist R-954 (Gobeil et al., 2014) , kindly provided by Dr Fernand Gobeil Jr (Pharmacology, Université de Sherbrooke, QC, Canada), was applied to unanaesthetized rats twice a day with one eye drop application (≈100 μg·10 μL À1 ) in both eyes during the last week prior to the experiments. R-954 was prepared in sterile saline solution and filtered (0.20 μm mesh). In addition, Ambion in vivo B 1 receptor siRNA (Invitrogen Life Technologies, Canada) was used to determine the efficacy of the B 1 receptor-siRNA strategy in reducing the mRNA levels of B 1 receptors, B 2 receptors, VEGF-A and VEGFR-2, in the retinas of STZ-diabetic rats by real-time quantitative RT-PCR (qRT-PCR) and to confirm the specificity of the polyclonal rabbit antiserum to rat B 1 receptors by immunocytochemistry (Supporting Information Figure S1 ). After anaesthesia with 3% isoflurane, a single intravitreal injection of siRNA (0.5, 1.0 or 10 nmol) on the day of STZ treatment for qRT-PCR and 2 days after STZ treatment for immunohistochemistry was performed. Rats were killed 1 week later, for the qRT-PCR or immunofluorescence analysis (see below).
No ocular irritation such as redness, porphyrin secretion or corneal opacity was seen 1 week after treatment with R-838, R-954 or B 1 receptor siRNA. In a previous study, s.c. administration of R-954 corrected the enhanced NO, kallikrein and vascular permeability in the retina of STZ-diabetic rats at 4 and 12 weeks (Catanzaro et al., 2012 (100 μg·μL À1 ) was applied on the surface of both eyes 1, 3
and 12 h (one rat for each time point) before the rat was killed to assess its ability to diffuse into the different structures. The cornea, vitreous, lens, retina and choroid from each eye of the STZ-treated rats were removed and digested in 300 μL of soluene (PerkinElmer, Boston, MA, USA) for 2 h at 37°C. A total of 5 mL of scintillation fluid (Ultimagold, Perkin Elmer, Boston, MA, USA) was added, and the radioactivity was counted in a scintillation counter (LS6500, Beckman Coulter, Mississauga, ON, Canada 
Immunofluorescent and immunocytochemistry staining
The specificity of the polyclonal rabbit antiserum for B 1 receptors was shown previously in B 1 receptor knockout (KO) mice tissues (Lin et al., 2010; Lacoste et al., 2013) and further determined in the present study using retina from wild-type (WT) and B 1 /B 2 receptor KO mice (provided by Dr Jean-Pierre Girolami, Université Paul Sabatier, Toulouse, France). In contrast to WT mice retina, B 1 receptor immunostaining was totally absent in the retina of B 1 /B 2 receptor KO mice (Supporting Information Figure S1 ). Furthermore, the specificity of the B 1 receptor antiserum was confirmed in STZ rat retina treated with B 1 receptor siRNA (10 nmol) showing a complete absence of B 1 receptor labelling. Also no staining was found in STZ rat retina incubated with the pre-immune serum as a negative control (Supporting Information Figure S1 ). For immunofluorescent staining, rats were perfused with a paraformaldehyde solution (2% PFA), and the eyes were dissected out, post-fixed in 2% PFA for 2 h and then frozen in isopentane (À55°C). Eyes were cut into 20-μm-thick sections with a cryostat and placed onto glass slides. Alternatively, they were embedded in paraffin after post-fixation, cut into 5-μm-thick sections and placed onto glass slides. The samples were treated to remove paraffin prior to the immunocytochemistry experiment. Tissue sections were incubated within a 20 mL staining dish containing sodium citrate buffer at 95°C. The citrate-based solution breaks the PFA-induced protein cross-links, therefore, unmasks the antigens and epitopes and enhances the intensity of staining of the antibodies. Sections were placed at room temperature (RT) and allowed to cool down for 20 min. Then, sections were washed for 10 min in 0.1 M PBS buffer (pH 7.4) and incubated for 1 h (RT) in blocking buffers (PBS containing 10% donkey serum and 0.25% triton X-100) to prevent non-specific labelling. Sections were incubated overnight at RT with the blocking buffer containing one of the following primary antibodies: BJP S Hachana et al.
polyclonal rabbit antiserum to rat B 1 receptor 1:150, mouse monoclonal anti-endothelial cells [rat endothelial cell antigen-1 (RECA-1), ab 9774; ABCAM] 1:500, mouse monoclonal anti-glial fibrillary acid protein (GFAP) (IF03L, Millipore Sigma) 1:500 to label astrocytes, mouse polyclonal anti-ionized calcium binding adapter molecule 1 (Iba-1; Wako, Richmond, VA, USA) 1:500 (2 μg·mL À1 ) to label microglia and chicken monoclonal anti-VEGFR-2 (GW21181, Sigma-Aldrich) 1:250. Afterwards, the slides were incubated for 2 h at RT with Alexa Fluor 488 donkey secondary antirabbit IgG (A21206, Invitrogen) to visualize B 1 receptors, with Alexa Fluor 555 donkey anti-mouse IgG (A31570, Invitrogen) to visualize endothelial cells, astrocytes and microglia and with Alexa Fluor 647 goat anti-chicken IgG (ab150175, Abcam) to visualize VEGFR-2. The slides were finally washed and mounted using ProLong® Gold Antifade Reagent (Invitrogen). Images were obtained with a confocal microscope Zeiss-LSM800 equipped with an argon laser. For the immunocytochemical study, tissue sections were prepared similarly. After incubation with the polyclonal rabbit antiserum to rat B 1 receptors 1:150, the sections were washed, and incubated with the appropriate biotinylated secondary antibody (1:200; Vectastain kit) for 2 h at RT. The slides were washed [PBS-T (0.25%)] and exposed to ABC solution (1%) (Vectastain, Vector Elite) for 1 h at RT. After being rinsed, the slides were exposed to diaminobenzidine (DAB/Vector peroxydase substrate Kit) chromogen for up to 10 min. The sections were rinsed for 5 min with PBS to stop the reaction. The slides were dehydrated with ethanol and cleared with xylene and then mounted using DPX mounting medium.
Quantification of B 1 receptors and Iba-1 immunolabelling
Microphotographs were obtained with a Leica microscope (Leica microsystems Co., Germany). Tissues from each experimental group were processed and imaged in parallel. The camera setting was identical for acquisition of images from all sections. Leica LCS Lite software was used to quantify the mean grey values in the retinal ganglion cell layer (GCL), the inner nuclear layer (INL) and the outer nuclear layer (ONL). Data are expressed as the mean pixel energy ratio from an average of 10 perikarya in the GCL or 20 perikarya in the INL and ONL for each retinal image quantified in four rats.
Measurement of retinal leukostasis
The rats were anaesthetized with urethane (1.5 g·kg À1 ), and a 16G cannula was inserted into the left heart ventricle. Rats were perfused with PBS over 1 min (35 mL·min À1 ). FITCcoupled concanavalin A lectin was infused (20 μg·mL À1 in PBS, 5 mg·kg À1 , 30 mL·min À1 ). Then 4% PFA was perfused for 1 min followed by albumin 1% in PBS for 1 min and by PBS for 2 min (35 mL·min À1 ). Eyes were removed, then the retinae were dissected out and flat mounted on a glass slide and imaged using a fluorescence microscope (Leica microsystems Co., Germany).
Measurement of retinal vascular permeability
Retinal vascular permeability was measured using the Evans blue dye technique as described previously (Pouliot et al., 2012) . The rats were anaesthetized with urethane (1.5 g·kg À1 ), and a catheter (Micro-Renathane, I.D. 0.040″, O.D. 0.020″, Braintree Scientific, Braintree, MA, USA) was inserted into the right femoral vein. Evans blue dye (45 mg·mL À1 in saline) (Sigma-Aldrich, Oakville, ON, Canada) was injected i.v. for 10 s, and 1.5 h later, saline (25 mL) was infused through the left heart ventricle to wash out intravascular dye. Eyes were removed, then the retina was dissected out and immediately weighed. Evans blue dye was then extracted by incubating each retina in 500 μL of formamide (Sigma-Aldrich, Oakville, ON, Canada) for 18 h at 70-75°C. The fluorescence of Evans blue was measured using a spectrofluorometer (Spex 1681 0.22 m, Horiba Jobin Yvon Inc, Edison, NJ, USA) using the wavelength of 620 nm (excitation) and 680 nm (emission).
Statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Data are expressed as mean ± SEM of values and 'n' refers to the number of rats for each set of experiments. Multiple comparisons between groups were performed using the non-parametric ANOVA Kruskal-Wallis test and post hoc Dunn's test for leukostasis and cellular distribution of B 1 receptors and microglia quantification. One-way ANOVA followed by the Bonferroni test was used for vascular permeability, Table 2 and gene expression when F achieved P < 0.05. Statistical analysis was performed using Prism ™ version 5.0 (GraphPad Software Inc., La Jolla, CA, USA). Only probability values (P) less than 0.05 were considered to be statistically significant.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
Blood glucose levels and body weight
Blood glucose concentrations were significantly increased while body weights were significantly decreased in STZ-diabetic rats at 2 weeks, 6 weeks and 6 months when compared to age-matched control rats (Table 2) . One week of treatment with R-838 or R-954 had no significant effect on glycaemia and body weight in STZ-diabetic rats and control rats.
Distribution of topically applied [ 3 H]-R-954
To make sure that the topically applied B 1 receptor antagonist on the ocular surface was able to reach the retina, we performed a preliminary experiment to evaluate the distribution of [ 3 H]-R-954 within the ocular compartments of STZdiabetic rat, at 1, 3 and 12 h post-administration. The results presented in Table 3 (Gobeil Jr. et al., 2014) , only its intact form can be found in each tissue compartment.
Effect of B 1 receptor stimulation on mRNA levels of kinin receptors and the VEGF system in the STZ-retina
Results depicted in Figure 1 showed significant and similar diabetes-induced increases (≈6-fold) of mRNA levels for B 1 receptors, B 2 receptors, VEGF-A and VEGFR-2 in the retina of 2 weeks STZ-diabetic rats compared to control retina.
Retinal mRNA levels of all these markers were significantly higher at 6 weeks than at 2 weeks in vehicle-injected STZdiabetic rats. Intravitreal injection of R-838 significantly further increased retinal mRNA levels of B 1 and B 2 receptors both at 2 and 6 weeks but not the mRNA of VEGF-A and VEGFR-2 when compared to vehicle-injected STZ-diabetic rats. The mRNA levels of the four markers in the retina of control rats were not changed by two intravitreal injections of R-838 at 48 h apart when compared to control vehicle at 2 weeks. However, R-838 caused a small but significant increase in B 1 and B 2 receptor mRNA levels in the 6 weeks control. B 1 receptors remained overexpressed (mRNA increased by ≈6-fold) at 6 months of diabetes, but the level of expression was not significantly enhanced by R-838 ( Figure 1A 0 ). In a separate series of experiments performed in 2 weeks STZ-diabetic rats, retinal mRNA levels of B 1 receptors, B 2 receptors, VEGF-A and VEGFR-2 were significantly increased (fourfold to sixfold) compared to control rats. These increases in STZ-retinas were dose-dependently prevented by B 1 receptor siRNA. Doses of 1.0 or 10 nmol of B 1 receptor siRNA totally prevented any increases in B 1 receptor, B 2 receptor, VEGF-A and VEGFR-2 mRNA expression ( Figure 1E ).
Table 2
Effects of diabetes and B 1 receptor agonist (R-838) and antagonist (R-954) treatments on body weight and glycaemia
Parameters
Ctl-vehicle (n = 6) Ctl-R-838 (n = 6) STZ-vehicle (n = 6) STZ-R-838 (n = 5) STZ-R-954 (n = 6) Values are in ng of [ 3 H]-R-954·g À1 wet tissue (μCi·g À1 wet tissue) calculated at 1, 3 and 12 h after eye drops application in STZ-diabetic rats (two eyes from one rat for each time point). The radioactivity was counted in each tissue, and the amount was expressed as a percentage of the total (%).
Effect of B 1 receptor agonist and antagonist on B 1 receptor immunoreactivity in the retina at 2 weeks of diabetes
The distribution of B 1 receptors in the retina and the intensity of staining in the different experimental conditions were studied by immunocytochemistry. The immunodetection of B 1 receptors was located mainly in vascularized layers of the retina, particularly in the retinal GCL, the INL and the ONL (Figure 2, upper panel) . While basal B 1 receptor immunostaining was virtually absent in the retina of control rats (Figure 2A) , it was intense in the retina of 2 weeks STZdiabetic rats ( Figure 2B ). Intravitreal treatment with R-838 further enhanced B 1 receptor staining intensity in the retina of STZ-diabetic rats ( Figure 2C ), while eye drops application of R-954 reduced it markedly in STZ-retina ( Figure 2D ). Semi-quantitative analysis showed significant increases in B 1 receptor immunolabeling in the three layers of the STZretina in comparison to control retina ( Figure 2E ). Treatment with R-838 did not significantly increase the B 1 receptor labelling in STZ-retina compared to the STZ group receiving vehicle despite a tendency in GCL and INL. In contrast, treatment with R-954 abolished the increases in B 1 receptor staining in GCL, INL and ONL in STZ-retina ( Figure 2E ).
Effect of B 1 receptor agonist and antagonist on retinal leukostasis at 2 weeks of diabetes
The pharmacological effect of R-838 and R-954 on leukocyte infiltration, which is an inflammatory event strongly involved in the pathogenesis of DR, was evaluated ( Figure 2 , middle panel). The leukocytes were labelled with FITC-concanavalin A lectin ( Figure 2A 0 -D 0 ). The number of adherent leukocytes to the retinal vascular endothelium was significantly higher ( Figure 2E 0 ) in STZ-diabetic retina compared to control. Although treatment with R-838 did not enhance further the leukostasis in the STZ-retina compared with vehicle-injected STZ-retina, R-954 significantly decreased leukocyte adherence and infiltration in STZ-diabetic retina. Some leukocytes were occasionally seen within the retinal tissue in STZ treated with R-838 ( Figure 2C 0 , arrowhead). This invasion of the retina by leukocytes indicates a strong inflammatory process controlled by B 1 receptors.
Effect of B 1 receptor agonist and antagonist on spatial distribution of microglia reactivity at 2 weeks of diabetes Microglia cells were found chiefly within the layer of neuronal fibres ( Figure 2A″ -D″, lower panel). In pathological conditions, these phagocytic cells can be present throughout the retina, where they produce not only pro-inflammatory cytokines but also factors that ensure the survival of vascular cells and neurons (Chen et al., 2002) . Here, we determined whether the B 1 receptor has an effect on microglia reactivity, an event that occurs early in the development of DR. In the retina of control rats, microglia morphology was characterized by a small soma with dense ramifications ( Figure 2A″ ). The microglia was distributed mainly in GCL ( Figure 2A″ -D″, E''). In the retina of 2 week STZ-diabetic rats, microglia cells were mostly ramified with some hypertrophic cell bodies and fewer processes ( Figure 2B″-D″) . The mean diameter of microglia was significantly enhanced (Figure 2F″) , and the majority of microglia was distributed in the INL, GCL and the ONL in the STZ-retina ( Figure 2E″ ). Treatment with R-838 or R-954 had no effect on microglia reactivity as shown by the intensity of Iba-1 labelling ( Figure 2C″ , D″), the mean diameter ( Figure 2F″ ) and the density ( Figure 2E″ ) of microglia cells, which were not significantly affected by B 1 receptor agonism and antagonism in 2 week STZ-retina.
Effect of B 1 receptor agonist and antagonist on retinal vascular permeability at 2 weeks of diabetes
Increased vascular permeability is an important dysfunction in the development of macular oedema in DR that contributes significantly to the reduction in vision. In this series of experiments, the pharmacological effect of a B 1 receptor agonist and antagonist on retinal vascular permeability was determined. In 2 week STZ-diabetic rats, retinal Evans Blue dye extravasation measured by spectrofluorometry was significantly increased compared to control rats (Figure 3 ). R-838 induced a significantly greater increase of retinal vascular permeability compared to vehicle-injected STZ-diabetic rats ( Figure 3A ). In contrast, eye drops treatment with R-954 significantly reduced, to near control values, the vascular hyperpermeability in the retina of STZ-diabetic rats ( Figure 3B ). Thus, topical application of R-954 appears a highly promising approach for the non-invasive treatment at the early stage of DR.
Co-localization of B 1 receptors on vascular endothelial and glial cells in the STZ-retina at 2 weeks of diabetes As shown by confocal microscopy, there was a very faint B 1 receptor staining in the control retina ( Figures 4A, 5A, 6A, 7A ). The B 1 receptor immunostaining was, however, strongly pronounced in the retina of the STZ rat in the nerve fibre, GCL and INL ( Figures 4D; 5D , D 0 , D″; 6D, D 0 ; 7D, G, J, M). In 2 week STZ-retina, there was a co-localization of immunofluorescence of B 1 receptors ( Figure 4F ) with endothelial cells labelled with the antibody RECA-1 ( Figure 4E ). This colocalization supports the hyperglycaemia-induced expression of B 1 receptors by endothelial cells in the STZ-retina. There was also a strong co-labelling of B 1 receptors ( Figure 5 F, F 0 , F″) and the GFAP marker ( Figure 5E , E 0 , E″), representative of astrocytes and activated Müller cells (Wang et al., 2010; Suzuki et al., 2014) , mainly in the internal border of the retina and GCL of diabetic retina. The GFAP labelling in the control retina was less intense and limited to low ramified glial extensions ( Figure 5B ) compared to the STZ retina where highly ramified and hypertrophic glial extensions were seen ( Figure 5E , E 0 , E″). VEGFR-2 exhibited weak immunostaining in control retina ( Figure 6B ), yet the intensity of labelling was increased in the diabetic retina ( Figure 6E ). Importantly, B 1 receptor staining did not show co-localization with VEGFR-2 on Müller cells and other retinal cells in both control and STZretina ( Figure 6C, F) . Intriguingly, B 1 receptors and VEGFR-2 seem to be co-expressed in blood vessels in STZ-retina ( Figure 6F 0 , arrow). This might suggest their joint effects in activating the vascular endothelium in diabetic retina. 
Absence of co-localization of B 1 receptors on microglia in the STZ-retina
In contrast to the low immunostaining for Iba 1 + microglial cells ( Figure 7B ) in control retina, a strong immunostaining was shown for microglial cells in the STZ-diabetic retina ( Figure 7E, H, K, N) . However, B 1 receptor (left panels) and Iba1 staining did not merge together in STZ-diabetic retina ( Figure 7F , I, L, O) and in control retina ( Figure 7C ), suggesting a distinct location of these markers. It is worth noting that the B 1 receptor was also seen on large cells within the GCL, which are most likely ganglion cells, based on their morphology ( Figure 7J arrow).
Discussion
This study supports a role for kinin B 1 receptors in retinal inflammation and the development of vascular alterations through a mechanism involving the endothelial and GFAPexpressing glial cells on which the B 1 receptor is expressed and up-regulated. However, the B 1 receptor is not present on microglia and does not seem to influence its reactivity. The B 1 receptor is proposed as a therapeutic target for the treatment of diabetic retinopathy as it is expressed at the very beginning of diabetes, an effect maintained during the progression of diabetes. This study also provides evidence that 1-week eye drops application of a water-soluble and metabolically stable peptide kinin B 1 receptor antagonist is an effective non-invasive approach to alleviate diabetesinduced retinal vascular inflammation.
Expression of B 1 receptor in various stages of diabetic retinopathy
Although earlier studies have shown that the B 1 receptor is up-regulated in the STZ-diabetic retina very early from 
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1-4 days to 6 weeks (Abdouh et al., 2003; Pouliot et al., 2011; , this is the first study showing that it remains overexpressed until a late (6 months) phase of STZ-induced diabetes. The agonist R-838 amplified retinal vascular permeability, leukostasis and B 1 receptor gene expression, suggesting that the B 1 receptor is functional and can respond to its agonist. The up-regulation of B 1 receptor gene expression by R-838 in STZ-retina is congruent with the auto-induction of B 1 receptors by its own agonists through the production of pro-inflammatory cytokines such as TNF-α and IL-1β (Schanstra et al., 1998; Phagoo et al., 1999) . This way, the B 1 receptor can amplify the pro-inflammatory process through a positive feedback loop mechanism . Indeed, the antagonist R-954 reversed the increased vascular permeability, leukostasis and immunocytochemical B 1 receptor protein expression, further suggesting that this receptor plays an important role in the pathological events of diabetes. In contrast, control rat retinal vessels did not express functional B 1 receptors, which is consistent with earlier studies in control rat retina at 1, 4, 7 and 21 days (Abdouh et al., 2003; Pouliot et al., 2011 Pouliot et al., , 2012 .
B 1 receptor pathway seems independent of VEGF pathway
The activation of B 1 receptors by intravitreal injection of R-838 failed to result in overexpressed VEGF and increased VEGFR-2 gene expression although they were suppressed following blockade of B 1 receptors with siRNA treatment or with LF22-0542 in the retina of STZ-diabetic rats (Pouliot et al., 2012). The lack of effect of R-838 on expression of VEGFR-2 is supported by the absence of co-localization of the two markers on retinal cells (except endothelial cells). The VEGF system is well known to stimulate microvascular permeability, vasodilatation and angiogenesis (Murakami, 2015) . VEGF also increases extravasation of plasma kallikrein into the retina, and plasma kallikrein is required for the full effects of VEGF on retinal vascular permeability and retinal thickening in rodents (Clermont et al., 2016) . Conversely, tissue kallikrein inhibits VEGF signalling via the cleavage of VEGF165 isoform, which may reduce retinal vascular permeability (Nakamura et al., 2011) . Importantly, BK-induced retinal thickening in mice was not affected by the blockade of VEGFR-2, and antagonists of B 1 receptors and B 2 receptors did not influence VEGF-induced retinal vascular permeability (Kita et al., 2015) . The latter study concluded that the plasma kallikrein-kinin system is implicated as a VEGF-independent mediator of diabetic macular oedema. Indeed, the strong expression of B 1 receptors on endothelial cells in STZ-retina is congruent with a direct effect of the B 1 receptor on capillary leakage that can occur independently of VEGF. The downregulation of the VEGF expression system by B 1 receptor antagonism or B 1 receptor gene deletion could merely derive from the inhibition of the inflammatory process.
Role of B 1 receptor in retinal vascular permeability and leukostasis
The breakdown of the blood-retinal barrier is an event that occurs early in the development of DR, and it is attributed to the increased production of pro-inflammatory cytokines and growth factors (Kern, 2007) . The increased vascular permeability may also be associated with changes in the expression of molecules that form the cell junctions of the blood-retinal barrier (Kern, 2007) . Studies have shown a decreased expression of occludin and ZO-1 in diabetic retinal endothelial cells, proteins that constitute the tight junctions (Antonetti et al., 1998; Barber et al., 2000) . In the present
Figure 6
Immunohistochemical distribution of VEGFR-2 and B 1 receptors (B1R). In control retina (A), B 1 receptor immunostaining was very weak and the overall B 1 receptor immunofluorescence intensity was higher in STZ-retina (D, D 0 ), particularly in the GCL of diabetic retina. Compared to control retina (B), VEGFR-2 immunofluorescence intensity increased in diabetic retina (E) notably in Müller cells process and in blood vessels (E 0 arrow). There is no co-localization between VEGFR-2 and B 1 receptors in control and STZ-retina on Müller cells and in GCL layer (C, F), but both colocalized on blood vessels in STZ-retina (F 0 ). Bar scale: 75 μm.
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S Hachana et al. Kinin B 1 receptor in STZ-diabetic retina BJP study, 1 week eye drops application of R-954 reversed increased retinal vascular permeability in 2 week STZ-diabetic rats without affecting glycaemia. This is in agreement with previous data using the high-affinity non-peptide B 1 receptor antagonist LF22-0542 (Pouliot et al., 2012) . Retinal vascular permeability was also decreased following systemic and intravitreal injection of a selective plasma kallikrein inhibitor in STZ-diabetic rats (Clermont et al., 2011) . The i.v. injection of R-954 was found to inhibit the enhanced vascular permeability in the retina of mice and rats treated with STZ 1 and 4 weeks earlier (Simard et al., 2002; Lawson et al., 2005) . Five consecutive s.c. injections of R-954 also reduced the enhanced levels of NO, kallikrein and vascular permeability and improved the reduced Na/K ATPase activity in diabetic rat retinae 4 and 12 weeks after STZ treatment (Catanzaro et al., 2012) . For the first time, our study shows that eye drops application of R-954 is a feasible approach that has the advantage of being less invasive, avoiding the risks associated with intravitreal injections (viral and bacterial infection and cataracts) and the systemic effects of i.v. treatments, particularly if the goal is to develop a therapeutic treatment.
The adhesion of leukocytes to the wall of blood vessels was suggested as one of the factors involved in endothelial cell death and may also contribute to alterations in retinal perfusion (Joussen et al., 2002; Kern, 2007) and increased vascular permeability (Del Maschio et al., 1996) . Evidence suggests that diabetic retinopathy is associated with increased levels of leukocytes in the retina and persistent leukostasis. Indeed, the number of neutrophils is significantly increased in the retinal blood vessels of diabetic patients and animals (McLeod et al., 1995; Miyamoto et al., 1998 Miyamoto et al., , 1999 . Local production of kinins and up-regulation of B 1 receptor expression in blood vessels contribute to the diapedesis of leukocytes and their migration into damaged tissues in response to the chemotactic attraction of cytokines (McLean et al., 2000) . The present study shows that treatment with R-954 reversed retinal leukostasis in STZ-diabetic retina. This finding highlights a primary role for B 1 receptors in the cellular inflammation associated with DR.
Co-localization of B 1 receptors on endothelial cells in the retina of STZ-diabetic rats B 1 receptor protein was mainly located in the retinal GCL, the INL, the ONL and the inner plexiform layer (IPL), representing the most vascularized retinal layers (except ONL) (Cuthbertson and Mandel, 1986) . R-954 downregulated the protein expression of B 1 receptors in the vascularized retinal layers. This may occur by preventing the auto-induction of B 1 receptors by its own agonist . Furthermore, the B 1 receptor was shown on endothelial cells and astrocytic end feet of retinal blood vessels, supporting its action on endothelial function and retinal vascular permeability. The overexpression of B 1 receptors in endothelial cells may also account for the alteration of retinal blood flow in the early phase of diabetes (Pouliot et al., 2011) . The vasodilatation of isolated retinal microvessels was mediated by the release of NO and prostaglandins derived from the COX-2 pathway in STZ-diabetic rats ( Co-localization of B 1 receptors on glial cells but not on microglia in the retina of STZ-diabetic rats Activated microglia are heavily involved in diabetes and retinal degeneration (Natoli et al., 2017) . In our study, microglia were identified by Iba-1 immunolabelling and showed the characteristics of activated microglia with hypertrophied cell body in STZ-diabetic retina unlike microglia in control rats displaying small size cytoplasm, in agreement with previous studies (Zeng et al., 2000; Krady et al., 2005) . At 2 weeks of diabetes, the majority of microglia were distributed in the inner retina, including GCL and the IPL, in both normal control and diabetic rats. At 12 weeks of diabetes, it was reported that the retinal microglia were more in the nerve fibre layer and GCL and less in the IPL; this is probably due to a redistribution associated with the reduction of the retinal thickness in the IPL (Chen et al., 2015) . Importantly, our findings showed that treatment with R-838 and R-954 did not alter retinal microglia reactivity as evidenced by the intensity of Iba-1 labelling, mean diameter and density of microglia in the three main vascular layers at 2 weeks of diabetes. Microglial cells are activated from the beginning of neuroinflammation (Graeber et al., 2011; Natoli et al., 2017) ; subsequently, astrocytes and Müller cells are activated to further accentuate the inflammatory process (Sorrentino et al., 2016) . The astrocytes are found mainly in the ganglion cell layer and the inner plexiform layer. These glial cells are in contact with the ganglion cells and surround the capillaries and contribute to the maintenance of the blood-retina barrier (Gardner et al., 1997; Wang et al., 2010) . Recent studies suggest that astrocytes are strongly activated during the inflammatory process via the NF-κB signalling pathway and contribute to the upregulation of inflammatory enzymes and mediators such as inducible NOS, TNF-α, IL-1β, IL-6 and IL-8 (Martorana et al., 2015; Zhong et al., 2016) . The activation of NF-κB and the subsequent release of pro-inflammatory cytokines are involved in the induction of the B 1 receptor that makes a link with astrogliosis. Müller cells expressing B 1 receptors also appeared to be activated since numerous GFAP hypertrophied cytoplasmic extension are seen throughout the tissue. The Müller cells also take part in the secretion of inflammatory mediators, which contribute to enhanced inflammation. They can be activated by microglia (Natoli et al., 2017) .
Hence, data show that the distribution and colocalization of B 1 receptor with retinal glial and Müller cells are strikingly correlated with the presence and distribution of retinal blood vessels. This provides a strategic role and mechanism for B 1 receptors in microvascular inflammation and endothelial dysfunction in the diabetic retina. Further investigations are needed to determine the occurrence and plasticity of B 1 receptor expression in other retinal cells (pericytes, photoreceptors and neurons) that can affect vision during diabetes.
Conclusion
This study shows that the B 1 receptor is up-regulated in retinal blood vessels including glial, Müller cells and particularly on endothelial cells, supporting a direct action of this BJP S Hachana et al.
receptor on blood vessels to enhance vascular permeability and leukostasis in STZ-diabetic retina. The B 1 receptor is also involved in the inflammatory cascade leading to its autoinduction and enhanced expression of B 2 receptors. In contrast, the B 1 receptor is not expressed on microglia in STZ-retina and its activation or inhibition failed to affect microgliosis. The functional overexpression of B 1 receptors in a late stage (6 months) of diabetes also suggests its involvement in the chronic phase of DR. Ocular application of the B 1 receptor antagonist R-954 by eye drops exerted antiinflammatory effects in STZ-diabetic retinopathy, providing a promising and non-invasive therapeutic approach for the treatment of diabetic retinopathy. Figure S1 Tests of specificity on the polyclonal rabbit antiserum to rat B 1 receptor. Upper panel: Representative images of immunofluorescent detection of B 1 receptor in control rat retina (A, D), STZ-retina (B, E) and STZ-retina treated with siRNA 10 nmol (C, F), sections were counter-stained for DAPI (blue). In contrast to the abundant B 1 receptor immunolabeling in STZ-retina, B 1 receptor immunostaining was absent in STZretina treated with siRNA. In control retina, B 1 receptor showed weak immunostaining. Middle panel: Immunohistochemical labelling (revealed with DAB) in control rat retina (A 0 ), STZ-retina (B 0 ) and STZ retina treated with pre-immune rabbit serum (C 0 ). The intensity of B 1 receptor immunostaining was greatly increased in STZ-retina compared to control retina. Conversely, no B 1 receptor labelling was detected in STZ-retina with the pre-immune rabbit serum. Bar scale: 75 μm. Bottom panel: Immunohistochemical labelling in wild-type mice retina (Wt; A″) and B 1 receptor/B2R-KO mice retina (B″). B 1 receptor staining in the GCL layer of Wt retina (arrows) was absent in B 1 receptor/B2R-KO mice retina (B″). This is consistent with the higher expression of B 1 receptor in mice than in rats . Bar scale: 75 μm.
